Delivery Order SPE2DB20D3103-SPE2DB23FL4G0
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,556,702,489 units of gabapentin 300 mg capsules. The $1,349.23 firm-fixed-price delivery order was placed under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,106.83 firm fixed-price delivery order is for the supply of 4,566,119,627 units of Gabapentin 300 mg capsules. The contract has an ultimate completion date of October 17, 2024 and was awarded on October 16, 2024. This award is a part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Delivery Order valued at $1,111.69 for the supply of 300 mg Gabapentin capsules. It is a Firm Fixed Price contract with a performance period through July 11, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,463.65 firm fixed-price delivery order is for the supply of 4,565,020,856 capsules of the medication Gabapentin 300 mg. The contract has a completion date of June 28, 2024 and was awarded on June 27, 2024. There was no set-aside designation used for this award. AmerisourceBergen holds a significant $999,999,999...
- This federal contract award, valued at $3,928.49, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4,567,118 units of gabapentin 300 mg capsules, a prescription medication used to treat certain types of nerve pain. The contract is a firm-fixed-price delivery order that runs through February 3, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $2,814.61, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which has a completion date of March 12, 2024, is a Delivery Order for the supply of GABAPENTIN 300 MG CAPSULE 1000S. This contract is not designated as a set-aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
- This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division, valued at $1,693.44, was issued by the Defense Logistics Agency (DLA) under a Delivery Order contract. The contract is for the supply of Gabapentin 300 mg capsules, a pharmaceutical product used to treat various neurological conditions. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution and healthcare solutions provider, to deliver Gabapentin 300 mg capsules. The $1,284.66 Firm Fixed Price Delivery Order contract has an ultimate completion date of January 24, 2024. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This federal contract award is for the delivery of GABAPENTIN 300 MG CAPSULE 1000S to the Defense Logistics Agency (DLA), a defense agency. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 4, 2024 with a completion date of June 5, 2024. The contract has a ceiling value of $3,292.42 and is a firm fixed-price delivery order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
- This is a $1,176.00 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is for the supply of 4,565,348,972 units of the prescription drug Gabapentin 300 mg capsules. The ultimate completion date for this order is August 6, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) to provide a wide range of...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB23FL4G0Delivery Order
This federal contract award is for the delivery of 4,558,864,433 units of gabapentin 300 mg capsules to the Defense Logistics Agency (DLA) Troop Support Medical. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on October 24, 2022, with a ceiling value of $1,680.74 and an ultimate completion date of October 25, 2022. The contract is a Delivery Order with a Firm Fixed Price pricing type and does not have a set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 10/24/22 |